Despite winning an FDA approval in 2023 and gaining clarity in May on the regulatory path forward for its Type 1 diabetes prospect sotagliflozin, Lexicon Pharmaceuticals hasn’t had an easy go of it in ...
Lexicon Pharmaceuticals announced that it will present data on diabetic peripheral neuropathic pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results